Biomarin Pharmaceutical Inc (BMRN)

pos +3.71
Today's Range: 111.05 - 116.70 | BMRN Avg Daily Volume: 1,275,400
Last Update: 03/05/15 - 4:00 PM EST
Volume: 2,777,946
YTD Performance: 21.45%
Open: $111.05
Previous Close: $109.79
52 Week Range: $55.04 - $111.89
Oustanding Shares: 159,135,697
Market Cap: 17,243,944,127
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 11 11 11
Moderate Buy 1 1 1 1
Hold 3 3 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.44 1.47 1.56 1.56
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -117.78
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-117.78 0.00 27.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
22.04% 35.85% 210.23%
Revenue 36.90 0.70 0.19
Net Income 0.00 1.49 0.00
EPS 0.00 0.92 0.00
Earnings for BMRN:
Revenue 0.75B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $-0.54 $-0.54 $-2.27 $-1.22
Number of Analysts 9 8 12 11
High Estimate $-0.27 $-0.33 $-1.53 $0.07
Low Estimate $-0.64 $-0.65 $-2.75 $-2.45
Prior Year $-0.27 $-0.19 $-0.77 $-2.27
Growth Rate (Year over Year) -100.82% -184.21% -194.37% 46.06%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Stocks that stabilized yesterday were terrific today.
Sector could regain its leadership role.
Watch this leadership group that's been lagging.
These are surefire indications of a bountiful tape.
Liquidity is crucial to maintaining trust in the system.
Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.
Stocks, like sports, are unfair sometimes. This is one of those times.
As 2014 winds down, you could almost throw darts at these standout groups -- but here are my own picks.
Nov 25, 2014 | 7:40 AM EST
BMRN price target raised to $100 from $87, said Jefferies. Favorable view following acquisition of Prosensa. Buy rating remains.
Nov 03, 2014 | 7:57 AM EST
BMRN was upgraded from Market Perform to Outperform, Wells Fargo said. Company has multiple potential clinical catalysts in 2015.

Columnist Conversations

Weyerhaeuser (WY) is seeing further weakness after penetrating the channel support I noted yesterday. It looks...
Blow off highs tend to take place on significant news days. In recent years, the monthly employment report ha...
Market trying to hold on to minor gains as we head into the close. Equities have been in a pretty narrow trad...
Shares near $4 and a buyer paid 50c for nearly 1500 Sep 5 calls to open a new position 25% above spot. Earning...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.